tldrdailynews.com logo

FDA Approves Toripalimab for Nasopharyngeal Carcinoma Treatment

1 min read
Source: Endpoints News
FDA Approves Toripalimab for Nasopharyngeal Carcinoma Treatment
Photo: Endpoints News
TL;DR

The FDA has approved toripalimab, a PD-1 inhibitor developed by Junshi Bio­sciences, for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC) in the US market. Co­herus Bio­Sciences holds the rights for the drug in the US and Canada and plans to launch it under the brand name Loqtorzi in the first quarter of 2024.

Topics:businesshealthcare#coherus-biosciences#fda#healthcare#junshi-biosciences#nasopharyngeal-carcinoma#toripalimab
Share this article
FDA approves Junshi, Coherus’ PD-1 toripalimab for nasopharyngeal carcinoma  Endpoints NewsView Full Coverage on Google News

Want the full story? Read the original reporting

Read on Endpoints News